Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138865 | 0.86 | GAA (0.41) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21138242 | 0.85 | GAA (0.40) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21138871 | 0.84 | GAA (0.54) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21138231 | 0.83 | GAA (0.53) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL19917032 | 0.82 | MAPT (0.52) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21138795 | 0.80 | ALDH1A1 (0.33) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21057527 | 0.79 | GAA (0.38) | GAAALDH1A1RAB9AHPGDPOLB | |
| SCHEMBL21057432 | 0.79 | GAA (0.43) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21057430 | 0.79 | GAA (0.43) | GAAALDH1A1RAB9ATP53HPGD | |
| SCHEMBL21138522 | 0.77 | GAA (0.38) | GAAALDH1A1RAB9AHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | GAA 1662/4885ALDH1A1 1644/4885RAB9A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.